- The FDA has accepted Unicycive Therapeutics' New Drug Application for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.